RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
RT @hhesterm: @Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. An…
@Channel4News The evaluations clearly have a strong effect on how companies price drugs in the UK, lowering their pricers. And because of this successful system UK drug prices are often used as reference prices by other countries, getting pharma to lower p
RT @PaulaLorgelly: @ruth_howells @PECjournal @RitaINdeFaria @NICEcomms As I said in my HTA Brexit paper .... https://t.co/joa10XSXZk
@ruth_howells @PECjournal @RitaINdeFaria @NICEcomms As I said in my HTA Brexit paper .... https://t.co/joa10XSXZk
RT @PaulaLorgelly: I should have made more of a #NoDeal in this paper, but who knew? I still believe anything but #NoBrexit will impact ac…
RT @PaulaLorgelly: I should have made more of a #NoDeal in this paper, but who knew? I still believe anything but #NoBrexit will impact ac…
I should have made more of a #NoDeal in this paper, but who knew? I still believe anything but #NoBrexit will impact access to new medicines. https://t.co/joa10XSXZk
RT @SullivanProf: Brexit, HTA and the cost of medicines in the future. Fascinating deconstruction of the issues by OHE and ICP’s Paula Lorg…
RT @ApplHealthEcon: For those who are missing @PaulaLorgelly's #HESGBristol plenary on #Brexit, here are some of her thoughts https://t.co/…
RT @ApplHealthEcon: For those who are missing @PaulaLorgelly's #HESGBristol plenary on #Brexit, here are some of her thoughts https://t.co/…
RT @ApplHealthEcon: For those who are missing @PaulaLorgelly's #HESGBristol plenary on #Brexit, here are some of her thoughts https://t.co/…
For those who are missing @PaulaLorgelly's #HESGBristol plenary on #Brexit, here are some of her thoughts https://t.co/uCdOXH8e9j https://t.co/p0SjJDgrKB
RT @SullivanProf: Brexit, HTA and the cost of medicines in the future. Fascinating deconstruction of the issues by OHE and ICP’s Paula Lorg…
Brexit, HTA and the cost of medicines in the future. Fascinating deconstruction of the issues by OHE and ICP’s Paula Lorgelly https://t.co/rKw3czMc1U
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @OHENews: 'The Impact of Brexit on Pharmaceuticals and HTA' - read @PaulaLorgelly's new article in PharmacoEconomics Open https://t.co/C…
RT @BenjaminKearns2: Well this is depressing (as if there weren't enough reasons to dislike Brexit already!) https://t.co/rE5xjuRVOz
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @ApplHealthEcon: The Impact of #Brexit on #Pharmaceuticals and #HTA by @PaulaLorgelly https://t.co/uCdOXH8e9j
Well this is depressing (as if there weren't enough reasons to dislike Brexit already!) https://t.co/rE5xjuRVOz
RT @OHENews: 'The Impact of Brexit on Pharmaceuticals and HTA' - read @PaulaLorgelly's new article in PharmacoEconomics Open https://t.co/C…
RT @OHENews: 'The Impact of Brexit on Pharmaceuticals and HTA' - read @PaulaLorgelly's new article in PharmacoEconomics Open https://t.co/C…
RT @OHENews: 'The Impact of Brexit on Pharmaceuticals and HTA' - read @PaulaLorgelly's new article in PharmacoEconomics Open https://t.co/C…
RT @OHENews: 'The Impact of Brexit on Pharmaceuticals and HTA' - read @PaulaLorgelly's new article in PharmacoEconomics Open https://t.co/C…
RT @OHENews: 'The Impact of Brexit on Pharmaceuticals and HTA' - read @PaulaLorgelly's new article in PharmacoEconomics Open https://t.co/C…
'The Impact of Brexit on Pharmaceuticals and HTA' - read @PaulaLorgelly's new article in PharmacoEconomics Open https://t.co/CQ8VYBJ6yX #healtheconomics #brexit
"Every cloud has a silver lining, but in truth it is difficult to find the opportunities for #HTA in #Brexit...but perhaps #HTA to benefit globally" https://t.co/7W1i02C21w
RT @ApplHealthEcon: The Impact of #Brexit on #Pharmaceuticals and #HTA by @PaulaLorgelly https://t.co/uCdOXH8e9j
RT @ApplHealthEcon: The Impact of #Brexit on #Pharmaceuticals and #HTA by @PaulaLorgelly https://t.co/uCdOXH8e9j
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
Guess what? #Brexshit will have a negative impact on health care in the UK. To be fair it will also have some positive impact - but only because it will increase drug costs. https://t.co/QpSFw8bZeV
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
"Maybe there will be a mass migration of health economists to Canada" ... and you would be welcome Tim @ApplHealthEcon ! #Brexit #HTA https://t.co/9UaFl0DzsH
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @EdudinGonzalo: @PaulaLorgelly explains some consequences of Brexit on the assessment of health technologies and pharmaceutical products…
RT @ApplHealthEcon: The Impact of #Brexit on #Pharmaceuticals and #HTA by @PaulaLorgelly https://t.co/uCdOXH8e9j
@PaulaLorgelly explains some consequences of Brexit on the assessment of health technologies and pharmaceutical products. The potential implications include more uncertainty, higher costs and less international relevance of the UK market and @NICEcomms
RT @ApplHealthEcon: The Impact of #Brexit on #Pharmaceuticals and #HTA by @PaulaLorgelly https://t.co/uCdOXH8e9j
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
Good read . Especially that it’s entirely speculative and then he confesses to being a bad bet . https://t.co/MKgb5qpcjX
RT @ApplHealthEcon: The Impact of #Brexit on #Pharmaceuticals and #HTA by @PaulaLorgelly https://t.co/uCdOXH8e9j
RT @PaulaLorgelly: My thoughts on #Brexit and #HTA. Taxi to the airport for me? https://t.co/iQaqTh4zVn
RT @ApplHealthEcon: The Impact of #Brexit on #Pharmaceuticals and #HTA by @PaulaLorgelly https://t.co/uCdOXH8e9j
RT @PaulaLorgelly: Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
RT @PaulaLorgelly: My thoughts on #Brexit and #HTA. Taxi to the airport for me? https://t.co/iQaqTh4zVn
Now it's there in print, I voted #Remain https://t.co/joa10XSXZk
My thoughts on #Brexit and #HTA. Taxi to the airport for me? https://t.co/iQaqTh4zVn
RT @ApplHealthEcon: The Impact of #Brexit on #Pharmaceuticals and #HTA by @PaulaLorgelly https://t.co/uCdOXH8e9j
"The cost of medicines and health care more generally will increase, the role of the National Institute for Health and Care Excellence (NICE) as a leading global HTA agency could be challenged, and the evidence base with which we do HTA will be impacted."
The Impact of #Brexit on #Pharmaceuticals and #HTA by @PaulaLorgelly https://t.co/uCdOXH8e9j
#HealthEconJA The Impact of Brexit on Pharmaceuticals and HTA https://t.co/lSkwBJMygC